In the Steno-2 trial, 160 individuals with type 2 diabetes mellitus, mostly in their 50s, were randomly assigned to multifactorial interventions or conventional care. Whereas microvascular and macrovascular complications were reduced during the 7.8 years of the trial period with intensive therapy, the observational follow-up data at 13.3 years and, now, 21 years demonstrate a benefit on mortality.
- Harpreet Bajaj
- Bernard Zinman
